Information de reference pour ce titreAccession Number: | 00000441-201205000-00007.
|
Author: | Rosenbaum, James MD; Chandran, Vinod MD
|
Institution: | Departments of Ophthalmology, Medicine, and Cell and Developmental Biology (JR), Oregon Health & Science University, Portland, Oregon; and the Department of Medicine (VC), University of Toronto, Toronto, Canada.
|
Title: | |
Source: | American Journal of the Medical Sciences. 343(5):364-366, May 2012.
|
Abstract: | The major comorbidities of ankylosing spondylitis include uveitis, bowel inflammation, psoriasis and heart disease. The pathogenic mechanism to account for the coexistence of comorbidities remains largely unknown. In some instances, the comorbidity has a major impact on the choice of therapy.
(C) Copyright 2012 Southern Society for Clinical Investigation
|
Author Keywords: | Ankylosing spondylitis; Uveitis; Inflammatory bowel disease; Osteoporosis; Atherosclerosis.
|
References: | 1. Bremander A, Petersson IF, Bergman S, et al.. Population-based estimates of common comorbidities and cardiovascular disease in ankylosing spondylitis. Arthritis Care Res (Hoboken) 2011;63:550-6.
2. Braun J, Baraliakos X, Listing J, et al.. Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 2005;52:2447-51.
3. Rudwaleit M, Baeten D. Ankylosing spondylitis and bowel disease. Best Pract Res Clin Rheumatol 2006;20:451-71.
4. Evans JM, McMahon AD, Murray FE, et al.. Non-steroidal anti-inflammatory drugs are associated with emergency admission to hospital for colitis due to inflammatory bowel disease. Gut 1997;40:619-22.
5. Talley NJ, Abreu MT, Achkar JP, et al.; American College of Gastroenterology IBD Task Force. An evidence-based systematic review on medical therapies for inflammatory bowel disease. Am J Gastroenterol 2011;106(suppl 1):S2-25; quiz S26.
6. Braun J, Baraliakos X, Listing J, et al.. Differences in the incidence of flares or new onset inflammatory bowel disease in patients with ankylosing spondylitis exposed to therapy with anti-tumor necrosis factor alpha agents. Arthritis Rheum 2007;57:639-47.
7. Mathieu S, Gossec L, Dougados M, et al.. Cardiovascular profile in ankylosing spondylitis: a systematic review and meta-analysis. Arthritis Care Res (Hoboken) 2011;63:557-63.
8. Peters MJ, Visman I, Nielen MM, et al.. Ankylosing spondylitis: a risk factor for myocardial infarction? Ann Rheum Dis 2010;69:579-81.
9. Vosse D, Landewe R, van der Heijde D, et al.. Ankylosing spondylitis and the risk of fracture: results from a large primary care-based nested case-control study. Ann Rheum Dis 2009;68:1839-42.
10. Maksymowych WP, Gladman D, Rahman P, et al.; Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada. The Canadian Rheumatology Association/Spondyloarthritis Research Consortium of Canada treatment recommendations for the management of spondyloarthritis: a national multidisciplinary stakeholder project. J Rheumatol 2007;34:2273-84.
11. Rosenzweig HL, Planck SR, Rosenbaum JT. NLRs in immune privileged sites. Curr Opin Pharmacol 2011;11:423-8.
12. Willingham SB, Allen IC, Bergstralh DT, et al.. NLRP3 (NALP3, Cryopyrin) facilitates in vivo caspase-1 activation, necrosis, and HMGB1 release via inflammasome-dependent and -independent pathways. J Immunol 2009;183:2008-15.
13. Keystone EC, Schorlemmer HU, Pope C, et al.. Zymosan-induced arthritis: a model of chronic proliferative arthritis following activation of the alternative pathway complement. Arthritis Rheum 1977;20:1396-401.
14. Martin TM, Zhang G, Luo J, et al.. A locus on chromosome 9p predisposes to a specific disease manifestation, acute anterior uveitis, in ankylosing spondylitis, a genetically complex, multisystem, inflammatory disease. Arthritis Rheum 2005;52:269-74.
15. Buzas EI, Brennan FR, Mikecz K, et al.. A proteoglycan (aggrecan)-specific T cell hybridoma induces arthritis in BALB/c mice. J Immunol 1995;155:2679-87.
16. van der Heijde D, Landewe R, Einstein S, et al.. Radiographic progression of ankylosing spondylitis after up to two years of treatment with etanercept. Arthritis Rheum 2008;58:1324-31.
17. Galor A, Perez VL, Hammel JP, et al.. Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 2006;113:2317-23.
18. Collamer AN, Guerrero KT, Henning JS, et al.. Psoriatic skin lesions induced by tumor necrosis factor antagonist therapy: a literature review and potential mechanisms of action. Arthritis Rheum 2008;59:996-1001.
19. Kezic JM, Davey MP, Glant TT, et al.. IFN[gamma] regulates discordant mechanisms of uveitis versus joint and axial disease in a murine model resembling spondyloarthritis. Arthritis Rehum 2012;64:767-771.
|
Language: | English.
|
Document Type: | Symposium Article.
|
Journal Subset: | Clinical Medicine.
|
ISSN: | 0002-9629
|
NLM Journal Code: | 3l2, 0370506
|
DOI Number: | https://dx.doi.org/10.1097/MAJ.0...- ouverture dans une nouvelle fenêtre
|
Annotation(s) | |
|
|